0.78
-0.0493(-5.96%)
Currency In USD
| Previous Close | 0.83 |
| Open | 0.82 |
| Day High | 0.82 |
| Day Low | 0.75 |
| 52-Week High | 2.48 |
| 52-Week Low | 0.63 |
| Volume | 615,360 |
| Average Volume | 931,050 |
| Market Cap | 16.39M |
| PE | 3.11 |
| EPS | 0.25 |
| Moving Average 50 Days | 0.79 |
| Moving Average 200 Days | 1.33 |
| Change | -0.05 |
If you invested $1000 in Longeveron Inc. (LGVN) since IPO date, it would be worth $10.5 as of October 19, 2025 at a share price of $0.778. Whereas If you bought $1000 worth of Longeveron Inc. (LGVN) shares 3 years ago, it would be worth $22.75 as of October 19, 2025 at a share price of $0.778.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
GlobeNewswire Inc.
Oct 06, 2025 1:15 PM GMT
MIAMI, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will pa
George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors
GlobeNewswire Inc.
Oct 01, 2025 8:05 PM GMT
Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Chairman, Longeveron Dr. George Paletta George Paletta, Jr., MD, MBA MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage bi
Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
GlobeNewswire Inc.
Sep 22, 2025 1:15 PM GMT
Exploring potential partnerships and strategic opportunities for the Company’s stem cell therapy program in Alzheimer’s diseaseAlzheimer’s disease development program with positive data in successful Phase 1 and Phase 2a clinical trialsClear regulato